Longevity & AgingSingle-Dose Gene Therapy Cuts LDL Cholesterol by 68% in Primate Study
A single injection of an experimental CRISPR-based therapy called STX-1150 reduced LDL cholesterol by up to 68% and a key cholesterol-regulating protein by up to 90% in non-human primates. Remarkably, even the lowest dose maintained more than 50% LDL reduction for over 22 months with effects still ongoing. Unlike traditional gene editing, this approach silences genes without permanently altering DNA, targeting the liver via lipid nanoparticles. The therapy showed no significant off-target effects or liver toxicity in preclinical tests. A first-in-human Phase 1 trial is now enrolling in Australia, with New Zealand sites planned. For the millions at risk from high LDL-driven cardiovascular disease, a durable single-dose treatment could be a game-changer compared to daily statins or biweekly injections.
